Tag Archives: Diabetes

Libre 2 Appears to Remain in US Soft Launch; When will Broad Launch Commence?

A series of events and observations have been made that suggest the Libre 2 US commercialization remains in a soft launch; however, a broad launch of the Libre 2 system may be in the near term. Below, FENIX provides analysis on the Libre 2 soft launch, potential insight into Abbott’s rationale to simultaneously market Libre 14-day and Libre 2, and thoughts on whether Abbott would minimize Libre 2 promotional efforts if Libre 3 US approval is around the corner.

This content is for Read Less members only.
Register

Already a member? Log in here

Virta Health Raises $65M in Series D Funding Round

Virta Health announced it raised $65M in a Series D funding round led by Sequoia Capital Global Equities and Caffeinated Capital which values Virta Health at >$1.1B. For context, Virta offers non-pharmaceutical coaching and lifestyle intervention program for chronic metabolic conditions, including T2DM, with the goal of improving patient health and reducing the need for some medications. Below, FENIX provides thoughts on Virta’s funding and valuation in the context of the recent Livongo/Teladoc merger as well as brief thoughts on the Virta value proposition.

This content is for Read Less members only.
Register

Already a member? Log in here

Pharmaceutical Strategies Group Launches “Total Cost of Diabetes Care” Feature for Health Plans and Employers

Pharmaceutical Strategies Group (PSG) announced the launch of a diabetes cost management tool, called “Total Cost of Diabetes Care,” designed for health plans and employers to manage the total cost of diabetes care among their users (view PSG website). Below, FENIX provides highlights from the press release as well as potential readthrough to companies like Livongo, Dario, and Onduo.

This content is for Read Less members only.
Register

Already a member? Log in here

Summary of Novartis Meet the Management Investor Event

Today, Novartis hosted its Meet the Management investor event and provided updates to its commercial and pipeline developments. Below, FENIX provides cardiometabolic-related highlights and insights from the event relating to Entresto, inclisiran (PCSK9i), and pelacarsen (LP(a)).

This content is for Read Less members only.
Register

Already a member? Log in here

Medtronic CY Q3 ’20 (FY Q2 ’21) Earnings Update; Dario Signs New Deal with Fortune 500 Company; Oramed Screens First Patients in the Ph3 ORMD-0801 Trial

A series of diabetes-related news items have been observed: Medtronic hosted its CY Q3 ’20 (FY Q2 ’21) earnings call (press release; slides); Dario signed a deal with a Fortune 500 company (press release); and Oramed announced it has screened the first patients in its Ph3 oral insulin (ORMD-0801) trial. Below, FENIX provides highlights and insights from the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here

Summary of Tirzepatide SURPASS Ph3 Event

Today, Lilly hosted a webcast presenting an overview of the Ph3 tirzepatide SURPASS program. Of note, Lilly highlighted that topline data from SURPASS-1 is anticipated in mid-December 2020 with US/EU filing in late 2021/early 2022. Below, FENIX provides highlights from the call as well as insights into the incretin dynamics in the T2DM space.

This content is for Read Less members only.
Register

Already a member? Log in here

Imeglimin Ph3 US and EU Development Discontinued by Metavant; Poxel Seeks Other Options

Poxel announced that Metavant, its US and EU development partner for Imeglimin, has decided not to move Imeglimin into Ph3 trials. Recall, in Poxel’s Q3 ’20 earnings update, Poxel disclosed that Metavant was in discussions with FDA regarding the Imeglimin Ph3 program in patients with T2DM and stage 3b or 4 CKD (previous FENIX insight). Below, FENIX provides thoughts on the future of Imeglimin in Western markets.

This content is for members only.
Register

Already a member? Log in here

Lilly Partners with Ypsomed for AID System; Tidepool Lays Off 40% of Staff

Two diabetes-related news items have been observed: Lilly and Ypsomed announced a partnership for the commercialization of Ypsomed’s AID system and Tidepool announced layoffs accounting for 40% of their staff. Below, FENIX provides highlights and insights for the respective news items, including thoughts on if the Lilly/Ypsomed partnership may be an admission from Lilly that its AID development is behind expectations and how the material experience of Mike Mason may have contributed to this deal getting done.

This content is for Read Less members only.
Register

Already a member? Log in here

Lexicon @ Stifel; First Presentation Since SOLOIST and SCORED Results

Lexicon participated in the 2020 Stifel Virtual Healthcare Conference and provided brief updates on its sotagliflozin strategy following the data readout from SOLOIST and SCORED. In case you missed it, here is a link to FENIX’s initial thoughts on the data. Below, FENIX provides highlights from Lexicon senior management’s commentary as well as an updated perspective and implications to sotagliflozin’s commercial prospects.

This content is for Read Less members only.
Register

Already a member? Log in here

EMPA-REG OUTCOME Post Hoc Analysis; Abbott Sponsors ADA Health Equity Initiative; Nemaura Launches BEAT Platform and Updated Company Website Ahead of US proBEAT Launch

Three diabetes-related news items have been observed: BI and Lilly announced results from a post hoc analysis of the EMPA-REG OUTCOME trial; Abbott and ADA announced Abbott is the first anchor sponsor of the Health Equity Now (HEN) platform with a $5M contribution towards addressing health disparities for PWD; and Nemaura Medical announced the relaunch of its company website and the launch of its BEAT diabetes website. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Register

Already a member? Log in here